News

Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors
The stock's fall snapped a two-day winning streak.
Regeneron declines to make higher bid for 23andMe after Wojcicki's $305 million offer
Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning ...
Regeneron is said to have declined a higher bid for 23andMe after Wojcicki's offer
Regeneron Pharmaceuticals (NASDAQ:REGN) has reportedly declined to submit a higher bid for 23andMe (OTC:MEHCQ) after a ...
Investing Snacks11h
Regeneron’s Stock Gets a Shot in the Wallet
Regeneron Pharmaceuticals took a modest hit as BDF Gestion reduced its stake by 11.5% in the first quarter, now holding $2.8 ...
Anne Wojcicki's bid to buy back 23andMe may not end a legal fight over DNA customer data
Anne Wojcicki’s winning bid to reclaim control of 23andMe doesn’t necessarily end the fight over what happens to the DNA of ...